This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print this page


    Page   1/1   
  • Value-based pharmaceutical pricing: Deloitte Insights video
    To transition from volume-based models to value-based pricing, companies must start with the basics. Watch this episode of Deloitte Insights to learn more.
  • Value-based pricing for pharmaceuticals: Implications of the shift from volume to value
    In a new value-driven health care system, payment linked to performance is a paradigm shift that calls for pharmaceutical companies to innovate in product commercialization and pricing. This Issue Brief summarizes what is known to date about value-based pricing and identifies opportunities for additional exploration.
  • Life sciences and health reform: No going back
    Tune into the latest episode of Deloitte Insights to learn more about the impact of health care reform on the life sciences industry.
  • Moving targets: Life sciences, health care reform and the new marketplace
    For life sciences companies, the 2010 Patient Protection and Affordable Care Act brings direct impacts. However, indirect impacts related to the changing nature of their relationships to other sectors and the choice and consumption of their products could be an even greater catalyst for transformation.
  • Page   1/1